{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:53:05Z","timestamp":1781527985935,"version":"3.54.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clbc.2026.04.005","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:05:57Z","timestamp":1776143157000},"page":"89-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune Checkpoint Inhibitors in Elderly Patients With Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Subgroup Evidence"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0012-2777","authenticated-orcid":false,"given":"Maria Isadora Rodrigues","family":"Carlos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0176-7077","authenticated-orcid":false,"given":"Julia Scaramal","family":"Mello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0905-8683","authenticated-orcid":false,"given":"Ana Luiza","family":"Mar\u00e7alo de Tolosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1655-0064","authenticated-orcid":false,"given":"Marina Romero","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1533-5834","authenticated-orcid":false,"given":"Becerra-Galindo","family":"Brando S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3436-9564","authenticated-orcid":false,"given":"Ana Cl\u00e1udia Rodrigues","family":"Carlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-8135","authenticated-orcid":false,"given":"Francisco Cezar Aquino","family":"de Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2026.04.005_sbref0001","series-title":"Breast cancer statistics","year":"2022"},{"key":"10.1016\/j.clbc.2026.04.005_sbref0002","series-title":"Key statistics for breast cancer","year":"2025"},{"key":"10.1016\/j.clbc.2026.04.005_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1244781","article-title":"Triple-negative breast cancer: from none to multiple therapeutic targets in two decades","volume":"13","author":"Carvalho","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.clbc.2026.04.005_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2020.576964","article-title":"Racial disparities in triple negative breast cancer: a review of the role of biologic and non-biologic factors","volume":"8","author":"Prakash","year":"2020","journal-title":"Front Public Health"},{"issue":"5","key":"10.1016\/j.clbc.2026.04.005_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128345","article-title":"Age-related disparity in immediate prognosis of patients with triple-negative breast cancer: a population-based study from SEER cancer registries","volume":"10","author":"Zhu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clbc.2026.04.005_bib0006","article-title":"Early-stage triple-negative breast cancer journey: beginning, end, and everything in between","volume":"43","author":"Han","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clbc.2026.04.005_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1060308","article-title":"PD-L1 expression as biomarker of efficacy of PD-1\/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: a systematic review and meta-analysis","volume":"14","author":"Khan","year":"2023","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.clbc.2026.04.005_bib0008","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1158\/1078-0432.CCR-08-2132","article-title":"Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes","volume":"15","author":"Rakha","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.clbc.2026.04.005_bib0009","article-title":"The differences in ultrasound and clinicopathological features between basal-like and normal-like subtypes of triple negative breast cancer","volume":"10","author":"Li","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clbc.2026.04.005_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.681476","article-title":"Current triple-negative breast cancer subtypes: dissecting the most aggressive form of breast cancer","volume":"11","author":"Ensenyat-Mendez","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.clbc.2026.04.005_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231953","article-title":"Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: implications for translational research","volume":"15","author":"Espinosa Fernandez","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.005_bib0012","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5858\/arpa.2019-0049-RA","article-title":"Microglandular adenosis and associated invasive carcinoma","volume":"144","author":"Kravtsov","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.clbc.2026.04.005_bib0013","series-title":"Essentials of Diagnostic Breast Pathology: A Practical Approach","author":"Moinfar","year":"2007"},{"issue":"8","key":"10.1016\/j.clbc.2026.04.005_bib0014","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/00000478-198307080-00002","article-title":"Microglandular adenosis of the breast. A clinicopathologic study of 11 cases with ultrastructural observations","volume":"7","author":"Tavassoli","year":"1983","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1016\/j.clbc.2026.04.005_bib0015","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2013.49.7693","article-title":"Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer","volume":"32","author":"de Melo Gagliato","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.005_bib0016","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/ijc.32788","article-title":"Association between initiation of adjuvant chemotherapy beyond 30\u2009days after surgery and overall survival among patients with triple-negative breast cancer","volume":"147","author":"Heeg","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clbc.2026.04.005_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.clbc.2026.04.005_bib0018","article-title":"Clinical progress of PD-1\/L1 inhibitors in breast cancer immunotherapy","volume":"11","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2026.04.005_bib0019","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.clbc.2026.04.005_bib0020","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2026.04.005_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.960323","article-title":"Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer","volume":"13","author":"Qi","year":"2022","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.clbc.2026.04.005_bib0022","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"10.1016\/j.clbc.2026.04.005_bib0023","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/jnci\/djab108","article-title":"PD-L1 immunohistochemistry assay comparison in Atezolizumab plus nab-paclitaxel-treated advanced triple-negative breast cancer","volume":"113","author":"Rugo","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.005_bib0024","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13058-023-01724-2","article-title":"Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms","volume":"25","author":"Sigurjonsdottir","year":"2023","journal-title":"Breast Cancer Res"},{"issue":"4","key":"10.1016\/j.clbc.2026.04.005_bib0025","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/jcp-2022-208637","article-title":"Comparison of assessment of programmed death-ligand 1 (PD-L1) status in triple-negative breast cancer biopsies and surgical specimens","volume":"77","author":"Noske","year":"2024","journal-title":"J Clin Pathol"},{"issue":"5","key":"10.1016\/j.clbc.2026.04.005_bib0026","doi-asserted-by":"crossref","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"10.1016\/j.clbc.2026.04.005_bib0027","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.005_bib0028","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2026.04.005_bib0029","unstructured":"National Cancer Institute. Overall survival. Bethesda, MD: National Cancer Institute. Dispon\u00edvel em: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/overall-survival"},{"key":"10.1016\/j.clbc.2026.04.005_bib0030","unstructured":"Cochrane Training. Risk of bias. London: Cochrane. Dispon\u00edvel em: https:\/\/www.cochrane.org\/learn\/courses-and-resources\/cochrane-methodology\/risk-bias."},{"issue":"7","key":"10.1016\/j.clbc.2026.04.005_bib0031","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.annonc.2024.04.001","article-title":"IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer","volume":"35","author":"Dent","year":"2024","journal-title":"Ann Oncol"},{"issue":"10265","key":"10.1016\/j.clbc.2026.04.005_bib0032","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clbc.2026.04.005_bib0033","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clbc.2026.04.005_bib0034","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.005_bib0035","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/jamaoncol.2023.5424","article-title":"Atezolizumab in combination with carboplatin and survival outcomes in patients with metastatic triple-negative breast cancer: the TBCRC 043 phase 2 randomized clinical trial","volume":"10","author":"Lehmann","year":"2024","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.clbc.2026.04.005_bib0036","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.clbc.2026.04.005_bib0037","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clbc.2026.04.005_bib0038","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/jamaoncol.2020.3524","article-title":"Effect of eribulin with or without pembrolizumab on progression-free survival for patients with hormone receptor\u2013positive, ERBB2-negative metastatic breast cancer: a randomized clinical trial","volume":"6","author":"Tolaney","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2026.04.005_bib0039","unstructured":"PROSPERO. https:\/\/www.crd.york.ac.uk\/prospero\/"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:02:21Z","timestamp":1781524941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926000571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1526820926000571"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.04.005","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Checkpoint Inhibitors in Elderly Patients With Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Subgroup Evidence","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}